Related Experiment Videos
Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma
Xiao-Yu Yin1, Ming-De Lü, Li-Jian Liang
1Department of Hepatobiliary Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China. yinxy@21cn.com
World Journal of Gastroenterology
|April 16, 2005
Summary
Systemic chemo-immunotherapy using the PIAF regimen showed therapeutic efficacy in advanced hepatocellular carcinoma (HCC). Patients receiving more cycles of this advanced HCC treatment experienced significantly improved survival rates.
Area of Science:
- Hepatobiliary Medicine
- Medical Oncology
- Clinical Immunology
Background:
- Advanced hepatocellular carcinoma (HCC) presents a significant therapeutic challenge.
- Systemic chemo-immunotherapy offers a potential treatment modality for advanced HCC.
Purpose of the Study:
- To evaluate the therapeutic efficacy of the PIAF chemo-immunotherapy regimen in patients with advanced HCC.
- To assess the impact of treatment duration on survival outcomes.
Main Methods:
- A cohort of 26 patients with advanced HCC received the PIAF regimen: cisplatin, doxorubicin, 5-fluorouracil, and human recombinant alpha-interferon-2a.
- Treatment was administered every 3 weeks for a maximum of six cycles.
- Patients were stratified into two groups based on the number of cycles received (six cycles vs. two to five cycles).
Main Results:
- The overall disease control rate was 50%, with 4 partial responses and 9 static diseases.
- The 1-year survival rate was 24.3%, with a median survival time of 6.0 months.
- Patients who completed six cycles (Group A) demonstrated significantly better survival outcomes compared to those who received fewer cycles (Group B), with a median survival of 12.5 months versus 5.0 months (P = 0.001).
Conclusions:
- Systemic chemo-immunotherapy with the PIAF regimen is an effective treatment for selected patients with advanced HCC.
- Completing the full treatment course is associated with improved survival rates and prolonged survival time.
- The PIAF regimen warrants further investigation for advanced HCC management.